Botox® (onabotulinumtoxinA) – New indication
February 10, 2021 - Allergan announced the FDA approval of Botox (onabotulinumtoxinA), for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Top